NASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free NEO Stock Alerts $15.72 +0.52 (+3.42%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$15.09▼$15.9150-Day Range$14.06▼$16.7952-Week Range$11.03▼$21.22Volume654,234 shsAverage Volume807,738 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$19.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeoGenomics alerts: Email Address NeoGenomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside22.3% Upside$19.22 Price TargetShort InterestBearish5.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 3 Articles This WeekInsider TradingSelling Shares$38,702 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.20) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.78 out of 5 starsMedical Sector738th out of 938 stocksTesting Laboratories Industry1st out of 1 stocks 2.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.22, NeoGenomics has a forecasted upside of 22.3% from its current price of $15.72.Amount of Analyst CoverageNeoGenomics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.71% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in NeoGenomics has recently increased by 3.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 1.9 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeoGenomics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat Follows7 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,702.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About NeoGenomics Stock (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesMarch 27, 2024 | businesswire.comNeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual MeetingMarch 25, 2024 | americanbankingnews.comNeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 21, 2024 | nasdaq.comCommit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using OptionsMarch 20, 2024 | msn.comNeogenomics Pokes Up On Unveiling ESG ReportMarch 20, 2024 | businesswire.comNeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) ReportMarch 14, 2024 | barrons.comNeoGenomics Inc.March 11, 2024 | au.finance.yahoo.comOmics Lab Services Market Report 2024 - Innovations in Genomics and Big Data AnalyticsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 1, 2024 | businesswire.comNeoGenomics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 28, 2024 | finance.yahoo.comWall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should KnowFebruary 23, 2024 | msn.comNeoGenomics (NEO) Price Target Increased by 6.33% to 21.79February 23, 2024 | finance.yahoo.comNEO Mar 2024 10.000 putFebruary 22, 2024 | finance.yahoo.comNeoGenomics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 21, 2024 | markets.businessinsider.comWhy Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?February 21, 2024 | marketwatch.comNeoGenomics Stock Rises on Earnings Beat, Upbeat GuidanceFebruary 21, 2024 | msn.comNeoGenomics shares jump after revenue forecast tops Street expectationsFebruary 21, 2024 | finance.yahoo.comNeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call TranscriptFebruary 21, 2024 | markets.businessinsider.comEvaluating NeoGenomics: Insights From 4 Financial AnalystsFebruary 21, 2024 | markets.businessinsider.comWhy NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketFebruary 21, 2024 | finance.yahoo.comQ4 2023 Neogenomics Inc Earnings CallFebruary 20, 2024 | finance.yahoo.comNeoGenomics (NEO) Q4 Earnings and Revenues Beat EstimatesFebruary 20, 2024 | finance.yahoo.comNeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesFebruary 20, 2024 | benzinga.comRecap: NeoGenomics Q4 EarningsFebruary 20, 2024 | sfgate.comNeoGenomics: Q4 Earnings SnapshotFebruary 20, 2024 | finance.yahoo.comNeoGenomics Reports Fourth Quarter and Full Year 2023 ResultsFebruary 20, 2024 | finance.yahoo.comNeoGenomics Inc (NEO) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full Year 2023See More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/29/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryN/A Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$19.22 High Stock Price Target$24.00 Low Stock Price Target$17.00 Potential Upside/Downside+22.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net Margins-14.87% Pretax Margin-16.41% Return on Equity-4.13% Return on Assets-2.33% Debt Debt-to-Equity Ratio0.57 Current Ratio6.20 Quick Ratio5.95 Sales & Book Value Annual Sales$591.64 million Price / Sales3.39 Cash Flow$0.29 per share Price / Cash Flow53.84 Book Value$7.39 per share Price / Book2.13Miscellaneous Outstanding Shares127,610,000Free Float125,951,000Market Cap$2.01 billion OptionableOptionable Beta1.10 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 61)CEO & Director Comp: $3.52MMr. Jeffrey S. Sherman M.B.A. (Age 58)Chief Financial Officer Comp: $492.31kMr. Warren Stone (Age 51)President of Clinical Division Comp: $722.79kGregory D. AunanSenior VP & Chief Accounting OfficerMs. Kendra SweeneyVice President of Investor Relations & CommunicationsMs. Alicia Olivo (Age 40)General Counsel & Corporate Secretary Mr. Hutan Hashemi J.D. (Age 45)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMs. Melody Harris Esq. (Age 58)J.D., President of Enterprise Operations Mr. Gary PassmanChief Culture OfficerMore ExecutivesKey CompetitorsMyriad GeneticsNASDAQ:MYGNTwist BioscienceNASDAQ:TWSTAvidity BiosciencesNASDAQ:RNAStructure TherapeuticsNASDAQ:GPCRNeumora TherapeuticsNASDAQ:NMRAView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 1,791 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Sold 146,536 shares on 3/11/2024Ownership: 11.104%Price T Rowe Associates Inc. MDBought 46,967 shares on 2/16/2024Ownership: 0.503%GSA Capital Partners LLPBought 11,479 shares on 2/16/2024Ownership: 0.009%O Dell Group LLCBought 1,750 shares on 2/16/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions NEO Stock Analysis - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price target for 2024? 11 brokers have issued 12-month price targets for NeoGenomics' shares. Their NEO share price targets range from $17.00 to $24.00. On average, they anticipate the company's share price to reach $19.22 in the next twelve months. This suggests a possible upside of 22.3% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2024? NeoGenomics' stock was trading at $16.18 at the start of the year. Since then, NEO stock has decreased by 2.8% and is now trading at $15.72. View the best growth stocks for 2024 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. NeoGenomics had a negative net margin of 14.87% and a negative trailing twelve-month return on equity of 4.13%. What ETFs hold NeoGenomics' stock? ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY). What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.12%), Vanguard Group Inc. (11.10%), Brown Advisory Inc. (7.57%), First Light Asset Management LLC (3.08%), Dimensional Fund Advisors LP (2.36%) and Schroder Investment Management Group (1.95%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does NeoGenomics have any subsidiaries? The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.Read More This page (NASDAQ:NEO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.